SCHEMBL12060

SCHEMBL12060

Cc1ccc(NCCN(C)C)nc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.57
HRH3 Q9Y5N1 1/20 0.49
RAB9A P51151 2/20 0.49
MAPT P10636 2/20 0.49
TDO2 P48775 1/20 0.46
DNM2 P50570 4/20 0.43
HRH4 Q9H3N8 1/20 0.42
KDM4E B2RXH2 3/20 0.41
PIM1 P11309 1/20 0.40
PIM3 Q86V86 1/20 0.40
PIM2 Q9P1W9 1/20 0.40
ALDH1A1 P00352 3/20 0.40
POLB P06746 1/20 0.40
RAD52 P43351 1/20 0.40
SMARCA2 P51531 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
ADRA2A P08913 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15743947 0.90 CYP2C19 (0.46) CYP2C19RAB9AMAPTDNM2KDM4E
SCHEMBL6645913 0.85 MAPT (0.53) RAB9AMAPTKDM4EALDH1A1GAA
SCHEMBL13086519 0.83 KDM4E (0.43) CYP2C19RAB9AMAPTKDM4EALDH1A1
SCHEMBL11447851 0.81 ALDH1A1 (0.43) CYP2C19RAB9AMAPTKDM4EALDH1A1
SCHEMBL15828790 0.81 CYP2C19 (0.56) CYP2C19HRH3RAB9AMAPTTDO2
SCHEMBL31260395 0.81 CYP2C19 (0.56) CYP2C19HRH3TDO2DNM2HRH4
SCHEMBL11446598 0.81 CYP2C19 (0.56) CYP2C19HRH3RAB9AMAPTTDO2
SCHEMBL3754896 0.81 CYP2C19 (0.56) CYP2C19HRH3TDO2DNM2HRH4
SCHEMBL2679914 0.81 CYP2C19 (0.56) CYP2C19HRH3TDO2DNM2HRH4
SCHEMBL29036800 0.81 CYP2C19 (0.56) CYP2C19HRH3TDO2DNM2HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3169687-B1 FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS ADVENCHEN PHARMACEUTICALS NANJING LTD (CN) 2019-01-02 EP disclosed
EP-3008045-B1 ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS ANTABIO SAS (FR) 2018-05-09 EP disclosed
US-9914712-B2 Antibacterial thiazolecarboxylic acids ANTABIO SAS (FR) 2018-03-13 US disclosed
US-9914712-B2 Antibacterial thiazolecarboxylic acids ANTABIO SAS (FR) 2018-03-13 US disclosed
US-20170174687-A1 FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS ADVENCHEN PHARMACEUTICALS NANJING LTD (CN) 2017-06-22 US disclosed
US-20170174687-A1 FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS ADVENCHEN PHARMACEUTICALS NANJING LTD (CN) 2017-06-22 US disclosed
US-20160272601-A1 Antibacterial Thiazolecarboxylic Acids ANTABIO SAS (FR) 2016-09-22 US disclosed
EP-2499146-B1 TRICYCLIC PYRAZOL AMINE DERIVATIVES MERCK SERONO SA (CH) 2016-09-21 EP disclosed
WO-2016010869-A2 FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS Advenchen Pharmaceuticals, LLC (US) 2016-01-21 WO disclosed
EP-2417140-B1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INT (DE) 2014-11-26 EP disclosed
US-8349839-B2 Inhibitors of HIV replication BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-08 US disclosed
US-8349839-B2 Inhibitors of HIV replication BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-08 US disclosed
US-8198456-B2 e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-12 US disclosed
WO-2011058149-A1 TRICYCLIC PYRAZOL AMINE DERIVATIVES MERCK SERONO S.A. (CH) 2011-05-19 WO disclosed
WO-2010115264-A1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 WO disclosed
US-20100261714-A1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 US disclosed
US-20100261714-A1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 US disclosed
US-20080176833-A1 DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-07-24 US disclosed
WO-2008071451-A1 DIHYDROPYRIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-06-19 WO disclosed
US-4203988-A ANTISECRETORY AGENTS MERCK & CO., INC. (US) 1980-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174687-A1 FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS MTOR, RICTOR, PIK3CA CYP2C19 1502/4885HRH3 2160/4885RAB9A 168/4885
US-20160272601-A1 Antibacterial Thiazolecarboxylic Acids ME1, TALDO1, COASY CYP2C19 896/4885HRH3 3046/4885RAB9A 2879/4885
US-20080176833-A1 DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS MET, DMPK, RET CYP2C19 2743/4885HRH3 1496/4885RAB9A 1898/4885
US-20100261714-A1 INHIBITORS OF HIV REPLICATION RTF2, POLR1A, REV1 CYP2C19 1139/4885HRH3 1136/4885RAB9A 1780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.